Author: Andi Thornton
A new phase 2 trial launched by Catalyst Pharmaceuticals
A new trial aimed at patients with type 3 SMA is being launched by Catalyst Pharmaceuticals for those living in both Italy and Serbia. The trial is designed to look at the efficacy of a drug called amifampridine.
Biogen to initiate phase 4 study in patients treated with Zolgensma
A new phase 4 trial for those who receiving gene therapy is planned to find out if additional treatment with Spinraza(R) could improve outcomes. Does this move spells that in future a multitreatment approach would be standard?
A new phase 2 trial launched by Catalyst Pharmaceuticals
A new trial aimed at patients with type 3 SMA is being launched by Catalyst Pharmaceuticals for those living in both Italy and Serbia. The trial is designed to look at the efficacy of a drug called amifampridine.
Biogen to initiate phase 4 study in patients treated with Zolgensma
A new phase 4 trial for those who receiving gene therapy is planned to find out if additional treatment with Spinraza(R) could improve outcomes. Does this move spells that in future a multitreatment approach would be standard?
TreatSMA introduces new member to the team
TreatSMA are really happy to announce Marion Main has formally joined the team and will take on the role as “TreatSMA Consultant Physio Therapist”
TreatSMA introduces new member to the team
TreatSMA are really happy to announce Marion Main has formally joined the team and will take on the role as “TreatSMA Consultant Physio Therapist”
TreatSMA is excited to announce a new network on clinical trials for children
c4c (conect4children) is a large collaborative European network that aims to facilitate the development of new drugs and other therapies for the entire paediatric population.
TreatSMA is excited to announce a new network on clinical trials for children
c4c (conect4children) is a large collaborative European network that aims to facilitate the development of new drugs and other therapies for the entire paediatric population.